Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Earnings for Rani Therapeutics Holdings, Inc. (RANI)
Earnings in 2023 (TTM): $-67,883,000
According to Rani Therapeutics Holdings, Inc.'s latest financial reports the company's current earnings (TTM) are $-67,883,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Rani Therapeutics Holdings, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-67,883,000 | $-33,970,000 |
| 2022 | $-63,274,000 | $-63,344,000 |
| 2021 | $-53,047,000 | $-53,088,000 |
| 2020 | $-16,668,000 | $-16,703,000 |
| 2019 | $-26,587,000 | $-26,597,000 |